Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults aged ≥ 18 years undergoing elective surgery at any surgical site
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (ages 18–36 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (age 18−47.3 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children under 18 years of age with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · men (ages > 18 years) with clinically localized prostate cancer
Posterior reconstruction showed no clear difference in serious adverse events compared with no posterior reconstruction (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Serious adverse events · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether retzius‐sparing RALP changes serious adverse events compared with standard RALP (very low certainty).
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Serious adverse events · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in serious adverse events (high certainty).
1 finding from 1 review
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · Children aged less than 5 years
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review